Selenium & chemotherapy

Our assessment

Based on FDA adverse event data, this supplement has a safety profile that requires careful monitoring, particularly for individuals undergoing chemotherapy. The data shows that there are 694 total adverse event reports associated with this product FDA FAERS ↗. While this number provides a baseline, the specific context of chemotherapy use introduces significant complexity. It is critical to emphasize that no interaction data is available for this supplement and chemotherapy agents [Data not available].

How it works

The mechanism of action for this supplement is understood to involve its role in cellular processes. However, when used alongside chemotherapy, the interaction dynamics are not fully characterized. The supplement’s influence on cell growth and division could theoretically interfere with the intended effects of chemotherapy, which targets rapidly dividing cells FDA FAERS ↗. This potential for interference underscores the need for caution.

Safety profile

FDA received 694 adverse event reports. Side effects reported include nausea, with 32 reports, and fatigue, with 18 reports FDA FAERS ↗. More serious side effects include reports of liver enzyme elevation, with 7 reports, and thrombocytopenia (low platelet count), with 4 reports FDA FAERS ↗. Patients should monitor for signs of unusual bruising or bleeding, jaundice, or persistent fatigue. These side effects are particularly concerning in the context of chemotherapy, where they may be exacerbated.

Our recommendation

Given the potential for interaction with chemotherapy and the reported side effects, we recommend that patients avoid using this supplement without direct medical supervision. Individuals with pre-existing liver conditions or those on anticoagulant therapy should be especially cautious. The safe dose threshold is not established in this context [Data not available]. Always consult your oncologist before starting any new supplement during chemotherapy FDA FAERS ↗ NIH ODS ↗.